Join Clinical Trials
  • Login
  • Home
  • Clinical Trial Categories
  • Clinical Trials by Condition
  • Cc
  • Carcinoma, Basal Cell


Menu

Choose Which Database to Search - Volunteer Database - Clinical Trial Database Create an Account - VOLUNTEER Accounts - RECRUITER Accounts Account Login - Volunteers Login - Recruiters Login Join a Clinical Trial Clinical Trials by Category Clinical Trials by Location Submit a Clinical Trial Frequently Asked Questions Contact Us Sitemap Blog

Categories

    Healthy Volunteers Adults - 18 - 64 Youths - Birth - 17 Seniors - 65 + Expanded Access Compensated Trials Clinical Trials by Condition Trials by Drug Type Trials for Rare Conditions

Recent Listings

  • Post your clinical trial on JoinClinicalTrials.com

    Ellijay, Georgia 30536
    United States

    Post your clinical trial on JoinClinicalTrials.com

    05-09-2019 01:01PM

JoinClinicalTrials.com





  • RCM to Diagnose BCC - Reflectance Confocal Microscopy to Diagnose Basal Cell Carcinoma
    NCT03331874
    Condition:   Basal Cell Carcinoma
    Intervention:   Diagnostic Test: Reflectance Confocal Microscopy
    Sponsor:   Julie Dawson
    Recruiting
  • A Study of IO103 in Montanide Adjuvant for Basal Cell Carcinoma
    NCT03714529
    Condition:   Basal Cell Carcinoma
    Intervention:   Biological: PD-L1
    Sponsors:   Herlev and Gentofte Hospital;   University of Copenhagen
    Recruiting
  • An Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC
    NCT04155190
    Condition:   Recurrent Basal Cell Carcinoma
    Interventions:   Drug: Patidegib Topical Gel, 2%;   Drug: Patidegib Topical Gel, Vehicle
    Sponsor:   PellePharm, Inc.
    Not yet recruiting
  • Nivolumab Alone or Plus Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
    NCT03521830
    Condition:   Basal Cell Carcinoma
    Interventions:   Drug: Nivolumab;   Drug: Ipilimumab
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;   Bristol-Myers Squibb
    Recruiting
  • The VIDYA Study-designed to Determine if Patients With a History of Basal Cell Carcinoma Are More Inclined to Return for Follow-up if Their Risk of a Subsequent Basal Cell Carcinoma is Quantitated.
    NCT04093401
    Condition:   Basal Cell Carcinoma
    Intervention:   Other: individualized risk assessment
    Sponsor:   University of Wisconsin, Madison
    Recruiting
  • Open-Label Dose Escalation Trial to Evaluate Dose Limiting Toxicity and Maximum Tolerated Dose of Microneedle Arrays Containing Doxorubicin (D-MNA) in Basal Cell Carcinoma
    NCT03646188
    Condition:   Basal Cell Carcinoma
    Interventions:   Drug: Placebo-containing MNA;   Drug: 25 µg doxorubicin-containing MNA;   Drug: 50 µg doxorubicin-containing MNA;   Drug: 100 µg doxorubicin-containing MNA;   Drug: 200 µg doxorubicin-containing MNA
    Sponsors:   SkinJect, Inc.;   University of Colorado, Denver
    Recruiting
  • Topical Remetinostat in Treating Patient With Cutaneous Basal Cell Cancer
    NCT03180528
    Condition:   Skin Basal Cell Carcinoma
    Intervention:   Drug: Remetinostat
    Sponsors:   Kavita Sarin;   Medivir
    Recruiting
  • Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT).
    NCT03573401
    Condition:   Superficial Basal Cell Carcinoma
    Interventions:   Combination Product: Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT);   Combination Product: Placebo Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)
    Sponsor:   Biofrontera Bioscience GmbH
    Recruiting
  • Arsenic Trioxide and Itraconazole in Treating Patients With Advanced Basal Cell Cancer
    NCT02699723
    Condition:   Skin Basal Cell Carcinoma
    Interventions:   Drug: Arsenic Trioxide;   Drug: Itraconazole;   Other: Laboratory Biomarker Analysis
    Sponsors:   Jean Yuh Tang;   National Cancer Institute (NCI)
    Not yet recruiting
  • (Cost)-Effectiveness of Optical Coherence Tomography (OCT) in Basal Cell Carcinoma (BCC)
    NCT03848078
    Conditions:   Basal Cell Carcinoma;   Optical Coherence Tomography
    Intervention:   Device: Optical Coherence Tomography
    Sponsors:   Maastricht University Medical Center;   ZonMw: The Netherlands Organisation for Health Research and Development
    Recruiting
  • Vitamin D as a Nutritional Neoadjuvant During Photodynamic Therapy of Basal Cell Carcinoma
    NCT03467789
    Conditions:   Basal Cell Carcinoma;   Basal Cell Nevus Syndrome
    Interventions:   Dietary Supplement: Vitamin D3 prior to first visit;   Dietary Supplement: Vitamin D3 prior to second visit;   Radiation: Photodynamic therapy;   Dietary Supplement: Maintenance Vitamin D3
    Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • A Study to Evaluate Neoadjuvant Sonidegib Followed by Surgery or Imiquimod in the Management of Basal Cell Carcinoma
    NCT03534947
    Conditions:   Basal Cell Carcinoma;   Basal Cell Carcinoma of Skin, Site Unspecified;   Skin Cancer;   Invasive Carcinoma
    Interventions:   Drug: Sonidegib;   Drug: Imiquimod;   Procedure: Surgery;   Other: Best supportive care
    Sponsor:   Melanoma Institute Australia
    Recruiting
  • Relationship Between Pharmacokinetics and Safety of Vismodegib - OPTIVISMO-1
    NCT03610022
    Conditions:   Metastatic Basal Cell Carcinoma;   Locally Advanced Basal Cell Carcinoma
    Intervention:   Drug: Treatment with vismodegib
    Sponsor:   University Hospital, Bordeaux
    Recruiting
  • Post-authorization Safety Study on the Long Term Safety of Sonidegib in Patients With Locally Advanced Cell Carcinoma
    NCT04066504
    Condition:   Basal Cell Carcinoma
    Intervention:   Drug: sonidegib
    Sponsor:   Sun Pharmaceutical Industries Limited
    Recruiting
  • Study Evaluating the Efficacy and Safety of 0.05% Ingenol Mebutate (Picato® 500) in the Treatment of Basal Cell Carcinoma
    NCT03546166
    Condition:   Carcinoma
    Intervention:   Drug: Picato 0.05% Topical Gel
    Sponsor:   Centre Hospitalier Universitaire de Nice
    Not yet recruiting
  • Vitamin D and Photodynamic Therapy for Treatment of BCC in BCNS
    NCT03483441
    Conditions:   Basal Cell Nevus Syndrome;   Basal Cell Carcinoma
    Interventions:   Other: Placebo pill;   Dietary Supplement: Vitamin D;   Drug: PDT
    Sponsors:   The Cleveland Clinic;   University of Arizona;   Harvard Medical School
    Recruiting
  • Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC)
    NCT03897036
    Condition:   Carcinoma, Basal Cell
    Intervention:   Drug: CX-4945
    Sponsor:   Senhwa Biosciences, Inc.
    Recruiting
  • Efficiency of Presurgical Basal Cell Carcinoma Margin Mapping
    NCT03420846
    Condition:   Carcinoma, Basal Cell
    Intervention:   Other: OCT Mapped
    Sponsors:   Michelson Diagnostics Ltd.;   Skin Care Network Ltd.
    Recruiting
  • Identification of Psychosocial Factors Associated With Diagnostic Delay in Advanced Basal Cell Carcinoma
    NCT04124796
    Condition:   Carcinoma, Basal Cell, Malignant
    Intervention:   Other: Semi-structured interviews
    Sponsors:   University Hospital, Bordeaux;   Bordeaux Population Health Research centre
    Recruiting
  • VISmodegib for ORbital and Periocular Basal Cell Carcinoma
    NCT02436408
    Condition:   Carcinoma, Basal Cell
    Intervention:   Drug: Vismodegib
    Sponsor:   University of Michigan Rogel Cancer Center
    Recruiting
  • French National Database of Rare Dermatological Cancers
    NCT03210935
    Conditions:   Adnexal Tumor of Skin;   Merkel Cell Carcinoma;   Advanced Basal Cell Carcinoma Requiring Systemic Treatment
    Intervention:  
    Sponsor:   University Hospital, Lille
    Recruiting
  • Topical Laser-assisted Combination Chemotherapy for Basal Cell Carcinoma― a Clinical Study
    NCT03541252
    Condition:   Carcinoma, Basal Cell
    Intervention:   Drug: AFL-assisted cisplatin+5-FU
    Sponsor:   Merete Haedersdal
    Recruiting
  • PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy
    NCT03132636
    Condition:   Carcinoma, Basal Cell
    Intervention:   Drug: REGN2810
    Sponsors:   Regeneron Pharmaceuticals;   Sanofi
    Recruiting
  • Diagnosing Melanoma, Squamous Cell Carcinoma and Basal Cell Carcinoma Using the Spectra-Scope
    NCT03069846
    Condition:   Skin Cancer
    Intervention:   Device: Spectra-Scope
    Sponsor:   Sung Hyun Pyun
    Recruiting
  • Use Of Oral Itraconazole In Patients With Locally Limited Basocellular Carcinoma Of Skin.
    NCT03972748
    Conditions:   Basal Cell Carcinoma;   Hedgehog Pathway
    Intervention:   Drug: Itraconazole 200 mg
    Sponsor:   Hospital de Clinicas de Porto Alegre
    Recruiting
  • Study Assessing the Safety and Performance of Smart Matrix®
    NCT03742726
    Conditions:   Basal Cell Carcinoma;   Squamous Cell Carcinoma
    Intervention:   Device: Smart Matrix scaffold
    Sponsor:   Smart Matrix Limited
    Recruiting
  • Molecular Characterization of Cutaneous Tumors
    NCT03092830
    Conditions:   Squamous Cell Carcinoma;   Basal Cell Carcinoma
    Intervention:   Genetic: Molecular testing of DNA/RNA from skin tumors, SCC/BCC
    Sponsor:   Rabin Medical Center
    Recruiting
  • Harmonics-based in Vivo Optical Virtual Biopsy
    NCT01980264
    Conditions:   Melanoma (Skin);   Basal Cell Carcinoma;   Squamous Cell Carcinoma
    Intervention:   Device: Harmonic Generation Microscopy
    Sponsors:   National Taiwan University Hospital;   National Health Research Institutes, Taiwan
    Recruiting
  • A Window of Opportunity Trial of Intratumoral Injection of Copaxone® in Patients With Percutaneously Accessible Tumors
    NCT03982212
    Conditions:   Cutaneous Squamous Cell Carcinoma;   Squamous Cell Carcinoma;   Basal Cell Carcinoma
    Intervention:   Drug: Copaxone
    Sponsor:   University of Kansas Medical Center
    Recruiting
  • Intraoperative Detection of Residual BCC by Fast Raman
    NCT03482622
    Conditions:   Carcinoma, Basal Cell;   Intraoperative BCC Detection by Fast Raman Device
    Intervention:   Diagnostic Test: Fast Raman
    Sponsors:   University of Nottingham;   Nottingham University Hospitals NHS Trust;   Circle Nottingham NHS Treatment Centre
    Not yet recruiting
  • Elucid Labs AIDA™ - Labelled Image Acquisition Protocol
    NCT03621462
    Conditions:   Melanoma (Skin);   Basal Cell Carcinoma of the Skin;   Squamous Cell Carcinoma of the Skin
    Intervention:   Device: Artificial Intelligence Dermatology Assistant (AIDA™)
    Sponsor:   Elucid Labs Inc.
    Not yet recruiting
  • T-VEC in Non-melanoma Skin Cancer
    NCT03458117
    Conditions:   Non-melanoma Skin Cancer;   Basal Cell Carcinoma;   Squamous Cell Carcinoma;   Cutaneous Lymphoma;   Merkel Cell Carcinoma
    Intervention:   Genetic: Talimogene Laherparepvec (T-VEC)
    Sponsor:   University of Zurich
    Recruiting
  • A Non-Interventional Pilot Study to Explore the Skin Microbes in Skin Cancer
    NCT04099446
    Conditions:   Skin Cancer;   Melanoma (Skin);   Squamous Cell Carcinoma;   Basal Cell Carcinoma;   Microbiome
    Intervention:   Other: Non-interventional
    Sponsor:   ProgenaBiome
    Not yet recruiting
  • Using MC1R Genotype to Impact Melanoma Risk Behavior
    NCT03509467
    Conditions:   Melanoma (Skin);   Squamous Cell Carcinoma;   Squamous Cell Cancer;   Skin Cancer;   Basal Cell Carcinoma;   Basal Cell Cancer
    Interventions:   Behavioral: Personalized Information;   Behavioral: Standard Information;   Other: DNA Extraction Determination of MC1R Genotypes
    Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   The Ponce Health Sciences University;   University of South Florida;   American Cancer Society, Inc.
    Recruiting
  • Cancer Risk in Carriers of the Gene for Xeroderma Pigmentosum
    NCT00046189
    Conditions:   Xeroderma Pigmentosum;   Basal Cell Carcinoma;   Squamous Cell Carcinoma;   Melanoma;   Skin Cancer
    Intervention:  
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers
    NCT03816332
    Conditions:   Clinical Stage III Cutaneous Melanoma AJCC v8;   Clinical Stage III Merkel Cell Carcinoma AJCC v8;   Clinical Stage IV Cutaneous Melanoma AJCC v8;   Clinical Stage IV Merkel Cell Carcinoma AJCC v8;   High-Frequency Microsatellite Instability;   Metastatic Basal Cell Carcinoma;   Metastatic Melanoma;   Metastatic Merkel Cell Carcinoma;   Metastatic Skin Squamous Cell Carcinoma;   Pathologic Stage III Cutaneous Melanoma AJCC v8;   Pathologic Stage III Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIIA Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIIB Cutaneous Melanoma AJCC v8;   Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8;   Pathologic Stage IIIC Cutaneous Melanoma AJCC v8;   Pathologic Stage IIID Cutaneous Melanoma AJCC v8;   Pathologic Stage IV Cutaneous Melanoma AJCC v8;   Pathologic Stage IV Merkel Cell Carcinoma AJCC v8;   Unresectable Basal Cell Carcinoma;   Unresectable Melanoma;   Unresectable Merkel Cell Carcinoma
    Interventions:   Biological: Ipilimumab;   Biological: Nivolumab;   Drug: Prednisone;   Drug: Tacrolimus
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • A Phase 1 Study of ZSP1602 in Participants With Advanced Solid Tumors
    NCT03734913
    Conditions:   Basal Cell Carcinoma;   Medulloblastoma;   Adenocarcinoma of Esophagogastric Junction;   Small Cell Lung Cancer;   Neuroendocrine Neoplasm;   Glioblastoma
    Intervention:   Drug: ZSP1602
    Sponsor:   Guangdong Zhongsheng Pharmaceutical Co., Ltd.
    Recruiting
  • How Microbes and Metabolism May Predict Skin Cancer Immunotherapy Outcomes
    NCT03370861
    Conditions:   Autoimmunity;   Melanoma;   Merkel Cell Carcinoma;   Squamous Cell Carcinoma of the Skin;   Basal Cell Carcinoma;   Skin Cancer
    Intervention:   Biological: Immunotherapy
    Sponsor:   Washington University School of Medicine
    Recruiting
  • Electronic Skin Surface Brachytherapy for Cutaneous Basal Cell and Squamous Cell Carcinoma
    NCT02131805
    Conditions:   Cutaneous Basal Cell;   Squamous Cell Carcinoma
    Interventions:   Radiation: Electronic Skin Surface Brachytherapy;   Behavioral: Quality of life assessment
    Sponsors:   Memorial Sloan Kettering Cancer Center;   Lynn Cancer Institute
    Recruiting
  • ACCEPTABILITY AND WRITING FREQUENCY OF ADVANCED DIRECTIVES IN ONCO-DERMATOLOGY PATIENTS
    NCT03822988
    Conditions:   Advance Directives;   Oncology;   Skin Cancer;   Melanoma;   Skin Lymphoma;   Skin Squamous Cell Carcinoma;   Metastatic Basal Cell Carcinoma
    Intervention:   Other: no intervention, only complete a survey
    Sponsor:   Central Hospital, Nancy, France
    Recruiting
  • Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or Lymphoma
    NCT03775525
    Conditions:   Advanced Cancer;   Gastric Cancer;   Breast Cancer;   Pancreatic Cancer;   Prostate Cancer Metastatic;   Colo-rectal Cancer;   Solid Tumor;   Solid Carcinoma;   Solid Carcinoma of Stomach;   Cancer of Stomach;   Lymphoma;   Sarcoma;   Cutaneous T Cell Lymphoma;   Head and Neck Squamous Cell Carcinoma;   Basal Cell Carcinoma;   Cutaneous T-cell Lymphoma;   Cutaneous Squamous Cell Carcinoma
    Intervention:   Drug: GZ17-6.02
    Sponsors:   Genzada Pharmaceuticals USA, Inc.;   Translational Drug Development
    Recruiting
  • Familial Investigations of Childhood Cancer Predisposition
    NCT03050268
    Conditions:   Acute Leukemia;   Adenomatous Polyposis;   Adrenocortical Carcinoma;   AML;   BAP1 Tumor Predisposition Syndrome;   Carney Complex;   Choroid Plexus Carcinoma;   Constitutional Mismatch Repair Deficiency Syndrome;   Diamond-Blackfan Anemia;   DICER1 Syndrome;   Dyskeratosis Congenita;   Emberger Syndrome;   Familial Acute Myeloid Leukemia;   Familial Adenomatous Polyposis;   Fanconi Anemia;   Familial Cancer;   Familial Wilms Tumor;   Familial Neuroblastoma;   GIST;   Hereditary Breast and Ovarian Cancer;   Hereditary Paraganglioma-Pheochromocytoma Syndrome;   Hodgkin Lymphoma;   Juvenile Polyposis;   Li-Fraumeni Syndrome;   Lynch Syndrome;   MDS;   Melanoma Syndrome;   Multiple Endocrine Neoplasia Type 1;   Multiple Endocrine Neoplasia Type 2;   Neuroblastoma;   Neurofibromatosis Type 1;   Neurofibromatosis Type II;   Nevoid Basal Cell Carcinoma Syndrome;   Non Hodgkin Lymphoma;   Noonan Syndrome and Other Rasopathy;   Overgrowth Syndromes;   Pancreatic Cancer;   Peutz-Jeghers Syndrome;   Pheochromocytoma/Paraganglioma;   PTEN Hamartoma Tumor Syndrome;   Retinoblastoma;   Rhabdoid Tumor Predisposition Syndrome;   Rhabdomyosarcoma;   Rothmund-Thomson Syndrome;   Tuberous Sclerosis;   Von Hippel-Lindau Disease
    Intervention:  
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting
  • Skin Cancer Prevention With Nicotinamide in Transplant Recipients - Pilot Trial
    NCT03769285
    Conditions:   Non-melanoma Skin Cancer;   Carcinoma, Squamous Cell;   Carcinoma, Basal Cell
    Interventions:   Drug: Nicotinamide;   Drug: Placebo oral capsule
    Sponsors:   Women's College Hospital;   Canadian Institutes of Health Research (CIHR);   The Kidney Foundation of Canada;   NOW Foods;   Natural Life Nutrition
    Recruiting
  • Tissue Sample Collection From Patients With Head and Neck Cancer and From Healthy Participants
    NCT00898638
    Condition:   Head and Neck Cancer
    Interventions:   Other: biologic sample preservation procedure;   Other: medical chart review
    Sponsors:   Vanderbilt University Medical Center;   National Cancer Institute (NCI)
    Recruiting
  • Alpha Radiation Emitters Device for the Treatment of of Malignant Cutaneous Tumors
    NCT04068155
    Conditions:   Skin Cancer;   Cutaneous Tumor;   Cutaneous Metastasis
    Intervention:   Device: DaRT- Diffusing Alpha-emitters Radiation Therapy
    Sponsor:   Alpha Tau Medical LTD.
    Not yet recruiting
  • Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia.
    NCT03889899
    Conditions:   Skin Cancer;   Mucosal Neoplasm of Oral Cavity;   Soft Tissue Neoplasm
    Intervention:   Device: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
    Sponsor:   Alpha Tau Medical LTD.
    Not yet recruiting
  • Alpha Radiation Emitters Device for the Treatment of Cutaneous, Mucosal and Superficial Soft Tissue Neoplasia (DaRT)
    NCT03886181
    Conditions:   Skin Cancer;   Mucosal Neoplasm of Oral Cavity;   Soft Tissue Neoplasm
    Intervention:   Device: Device: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
    Sponsor:   Alpha Tau Medical LTD.
    Not yet recruiting
  • Alpha Radiation Emitters Device for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia (DaRT)
    NCT03737734
    Conditions:   Skin Cancer;   Mucosal Neoplasm of Oral Cavity;   Soft Tissue Neoplasm
    Intervention:   Device: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
    Sponsor:   Alpha Tau Medical LTD.
    Recruiting

Popular Now

  • Privacy Policy
  • Ad and Cookie Policy
  • Infringement Policy
  • Terms of Use
  • Email Policy
  • Contact Us
  • Post Clinical Trials
  • Join Clinical Trials
  • Volunteer Login
  • Recruiters Login
  • Frequently Asked Questions
  • Blog
  • Find Clinical Trials
  • Find Volunteers
  • Trials by Category
  • Trials by Location
  • Volunteers by Category
  • Volunteers by Location
All clinical trials are registered and certified with clinicaltrials.gov. Data via U.S. National Library of Medicine,U.S. National Institutes of Health, U.S. Department of Health & Human Services. JoinClinicaltrials.com (Aunica Media llc) is a free resource that provides individuals and companies with information regarding clinical trials that are being conducted nationwide. Aunica Media llc does not conduct clinical trials nor endorses them. Please consult your doctor or physician before participating. And Ye shall know the truth, and the truth shall make you free
©2001-2019 Aunica Media LLC